Freshworks Inc vs Neurocrine Biosciences Inc — how do they compare? Freshworks Inc trades at $11.65 (market cap $3.31B), while Neurocrine Biosciences Inc trades at $158.46 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 5× Freshworks Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| FRSH | NBIX | |
|---|---|---|
Market Cap | $3.31B | $16.46B |
Sector | Technology | Health |
52-Week High | $13.97 | $185.50 |
52-Week Low | $6.88 | $123.10 |
Enterprise Value | $2.68B | $16.48B |
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $11.98, up 1.18% with bullish technical signals and strong fundamentals. The company reported Q2 2026 revenue growth of 16% year-over-year, achieving its first GAAP profitability quarter with $3.2 million net income. Recent FedRAMP designation and Gartner leadership recognition highlight strategic progress. Analyst consensus shows 50% buy ratings with a $16.50 price target, suggesting 38% upside potential.
The outlook remains positive with accelerating revenue growth and improved profitability, though elevated P/E and EV/EBITDA ratios warrant caution. Key risks include competitive pressures in SaaS and execution challenges. Current momentum supports continued appreciation toward analyst targets, making FRSH attractive for growth-oriented investors despite valuation concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →